Mundipharma announced that laboratory testing at the Duke-NUS Medical School in Singapore has confirmed the effectiveness of its Betadine antiseptic products against the novel coronavirus (SARS-CoV-2).
Testing has demonstrated Betadine strong in-vitro virucidal activity, killing 99.99% of the SARS-CoV-2 virus in 30 seconds. The products subjected to testing were: Betadine antiseptic products, namely solution (10% PVP-I), skin cleanser (7.5% PVP-I), gargle and mouthwash (1.0% PVP-I) and throat spray (0.45% PVP-I).
The research has been published in the respected Infectious Disease and Therapy Journal on July 8, 2020.
“These results confirm our view that Betadine antiseptic products, used appropriately and in conjunction with other preventative treatment options including PPE, can play a role in limiting the spread of infections, including COVID-19,” said Raman Singh, CEO of Mundipharma. “It also provides the medical community as well as consumers with a science-based assurance that they are using a product that is a proven defense against COVID-19.”
The study conducted at Duke-NUS is complemented by laboratory testing completed at the Tropical Infectious Diseases Research and Education Center (TIDREC) at the University of Malaya, Malaysia, that also demonstrated strong in-vitro virucidal activity, with the tested product Betadine Gargle and Mouthwash (1.0% PVP-I) killing 99.99% of the SARS-CoV-2 virus in 15 seconds. The TIDREC research has been accepted by the British Dental Journal (BDJ) and was published as a Letter on 26 June 2020.